We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Medical

Anastasis Biotec

Status: Active

Aug 3rd 2020 - Sep 3rd 2020

Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.

read more read less

Anastasis Biotec Rating Review

Pitch rating powered by CROWDRATING

Rated on 12/08/2020

Pitch Rated

53%

Insufficient Data

Management

87%

Product

72%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Log in to view amount pledged

    Log in to view target

    £8,520,520
    pre-money valuation

    1.73%
    equity available

    829
    investors

    £326
    pledge per investor

    10502511
    company number

    Active
    company status

    29/11/2016
    incorporated 7 years

    £2.65
    share price

    Previous Funding rounds
    28 Mar 24 Crowdcube £270,543 / 180% 53.00%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 87%

Skills 82%
The management of the company has a balance of scientific, medical, and business skills within the company to execute its drug development programs with confidence. The CEO/Chairman is a successful biotechnology entrepreneur and qualified medical oncologist who has previously developed new drugs through to commercial production. The COO is a biotechnology innovator specialising in Antibody (Ab) technologies in oncology, Ab-Drug Conjugate (ADC), Ab discovery, immuno-oncology, glycoengineering and small molecule technologies. He oversees research and development, financial and logistical activities of the company under contract with his company Antikor Limited. He is involved in successful biotech start-ups and is a director of a commercial R&D laboratory. The Executive Director has expertise in legal, IPR, corporate governance and fundraising logistics. The finance head is a qualified accountant with M&A and investor relations experience in an FTSE 100 company. It was noted that they have not appointed a dedicated marketing head.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


Log in to view amount pledged

    Log in to view target

    £8,520,520
    pre-money valuation

    1.73%
    equity available

    829
    investors

    £326
    pledge per investor

    10502511
    company number

    Active
    company status

    29/11/2016
    incorporated 7 years

    £2.65
    share price

    Previous Funding rounds
    28 Mar 24 Crowdcube £270,543 / 180% 53.00%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph